Preclinical data evaluate lysophosphatidylcholine-bound EPA and DHA delivery via Lysoveta platform

Recent research into omega-3 lipid delivery has evaluated the transport kinetics of lysophosphatidylcholine (LPC)-bound eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), assessing how specific molecular carriers facilitate passage across the blood-brain barrier (BBB). The investigations, focused on Aker BioMarine's proprietary Lysoveta ingredient, assessed uptake mediated by the major facilitator superfamily domain-containing protein 2a (Mfsd2a) transporter. Unlike standard dietary formats of omega-3s—such as conventional triglycerides, ethyl esters, and standard diacyl-phospholipids—LPC-bound fatty acids act as the primary physiological substrate for Mfsd2a, which regulates targeted DHA and EPA transport into cerebral tissue. ### Mechanism and comparative transport While conventional long-chain polyunsaturated fatty acid (LC-PUFA) supplementation elevates systemic circulating concentrations, passage into central nervous system tissues is constrained by BBB selectivity. Preclinical findings suggest that delivering omega-3s on a monoacyl LPC backbone bypasses the rate-limiting hydrolytic stages required for unesterified free fatty acids, facilitating direct translocation via Mfsd2a receptors expressed on cerebral microvascular endothelial cells. In comparative animal models, LPC-bound EPA and DHA yielded higher relative accumulation in cerebral structures than equivalent doses administered as conventional fish oil triglycerides or ethyl ester concentrates. ### Formulator and commercial implications For dietary supplement formulators and brand owners, the emergence of commercial-scale LPC lipid complexes offers an alternative pathway for targeted delivery within the cognitive and neurological wellness category. While standard omega-3 concentrates remain mainstream commercial staples, demand for specialised formats with differentiated pharmacokinetic profiles continues to expand. However, commercial uptake remains contingent on further human clinical validation, product stability within standard delivery systems (such as softgels or specialised lipid capsules), and compliance with regional regulatory frameworks. Under European Food Safety Authority (EFSA) and UK Food Standards Agency (FSA) rules, commercial finished goods cannot claim therapeutic action against neurodegenerative diseases. Brand owners must rely on authorised Article 13 general function claims for DHA in maintaining normal brain function, unless ingredient-specific novel food authorisations and proprietary health claims are secured.